Biomerica, Inc. Aktie News

- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributors - Relationship Marks a Key Milestone in Biomerica's Commercialization Strategy

Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company's Ongoing Focus on Cost Reduction and Operational Efficiency Earnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif.

IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and healthcare services industry, including serving as Chief Executive Officer of LabCorp Dia...

IRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods® IBS Trigger Food Navigator, a comprehensive AI-backed digital companion tool designed to better enable patient dietary compliance and improve treatment success for individuals with Irritable Bowel Syndro...

IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use. This important regulatory milestone expands access to accurate, easy-to-use diagnostic tools supporting early ident...

$1.3 Million in Operating Expense Reductions Achieved– Operating Loss Improves 19% Year-Over-Year Resilient Portfolio Performance with International Sales Despite Global Economic Uncertainties Cash Used in Operating Activities Reduced to $3.8 Million vs. $5.3 Million in the Prior Year, Reflecting Stronger Operating Discipline IRVINE, Calif.

IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved Biomerica's Fortel® Ulcer Test for home use. This marks a milestone in expanding access to accurate, easy-to-use diagnostic tools for one of the leading causes of g...

IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company focused on innovative gastroenterology diagnostics, today announced that the American Medical Association CPT editorial panel has issued a Current Procedural Terminology (CPT®) code in the Proprietary Laboratory Analysis (PLA) code category for the Company's inFoods® IBS test.